Idorsia effectively started its operations after demerging from Actelion on June 15, 2017, and registered shares of Idorsia Ltd were listed on the SIX Swiss Exchange the next day. Today, Idorsia has an experienced team of highly qualified professionals, a full R&D pipeline with 4 clinical assets expected to advance into Phase 3 in 2018, state of-the-art facilities, and a strong balance sheet – the ideal constellation for bringing successful medicines to the market.


For the first quarter 2018, US GAAP operating loss amounted to CHF 74 million and non-GAAP operating loss amounted to CHF 67 million. US GAAP operating loss is based on revenues of CHF 7 million, non-GAAP R&D expenses of CHF 61 million, non-GAAP G&A expenses of CHF 12 million, depreciation and amortization of CHF 5 million, and share-based compensation of CHF 3 million.

The US GAAP net loss amounted to CHF 79 million resulting in a net loss per share of CHF 0.66.

As of March 31, 2018, Idorsia’s liquidity (including cash, cash equivalents, short- and long-term deposits) amounted to CHF 1,016 million.

 

 Idorsia's key numbers

First quarter 2018*

(in CHF millions, except EPS)

US GAAP

Non-GAAP

Revenues

7

7

Operating expenses

(81)

(73)

Operating income (loss)

(74)

(67)

Net income (loss)

(79)

(69)

Basic EPS

(0.66)

(0.58)

Baisc number of shares (weighted average)

119.1

119.1

Diluted EPS

(0.66)

(0.58)

Diluted number of shares (weighted average)

119.1

119.1

 

Idorsia measures, reports and issues guidance on non-GAAP operating performance. Idorsia believes that these non-GAAP financial measurements more accurately reflect the underlying business performance and therefore provide useful supplementary information to investors. These non-GAAP measures are reported in addition to, not as a substitute for, US GAAP financial performance.